Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Cirrhosis, hepatitis infection and other causes can trigger liver fibrosis—a potentially lethal stiffening of tissue that, ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

ALT measured subjects’ fat content and alanine aminotransferase [ALT] and corrected T1 [cT1] to evaluate inflammation and ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...